PMID- 33099954
OWN - NLM
STAT- MEDLINE
DCOM- 20210721
LR  - 20211204
IS  - 2241-6293 (Electronic)
IS  - 1107-0625 (Linking)
VI  - 25
IP  - 4
DP  - 2020 Jul-Aug
TI  - Metformin induces apoptosis of melanoma B16 cells via PI3K/Akt/mTOR signaling 
      pathways.
PG  - 2066-2070
AB  - PURPOSE: To investigate the influences of metformin on the proliferation and 
      apoptosis of mouse melanoma B16 cells through regulating the phosphatidylinositol 
      3-hydroxy kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin 
      (mTOR) signaling pathway. METHODS: The mouse melanoma B16 cell strains were taken 
      as the subjects of the study, and were randomly divided into the control group 
      with RPMI-640 medium with the volume same with that in the metformin group (C 
      group, n=6) and Q group [metformin:10 mmol/L (Q1 group, n=6), metformin:20 mmol/L 
      (Q2 group, n=6), and metformin:40 mmol/L (Q3 group, n=6)]. The cell counting 
      kit-8 (CCK-8) method was employed to detect the proliferation of cells in each 
      group at different culture times. The apoptosis of cells in each group was 
      detected via flow cytometry and terminal deoxynucleotidyl transferase-mediated 
      dUTP nick end labeling (TUNEL). RESULTS: The proliferation rate in Q group was 
      lower than in C group, and the difference was statistically significant (p<0.05 
      or p<0.01). According to the results of flow cytometry, it was concluded that the 
      number of apoptotic cells in Q group was higher than in C group (p<0.05 or 
      p<0.01). TUNEL results revealed that compared with that in C group, the apoptosis 
      rate in Q group was increased (p<0.05 or p<0.01). Moreover, western blotting 
      results showed that the protein expression levels of PI3K, Akt and mTOR in Q 
      group were higher than in C group. CONCLUSIONS: Metformin can inhibit the 
      proliferation of mouse melanoma B16 cells and induce their apoptosis probably 
      through its regulation on the PI3K/AKT/mTOR signaling pathway in cells.
FAU - Tian, Ye
AU  - Tian Y
AD  - Department of Dermatology, Dongzhimen Hospital Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Zhao, Lili
AU  - Zhao L
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Melanoma, Experimental/*drug therapy/metabolism/pathology
MH  - Metformin/*pharmacology
MH  - Mice
MH  - Phosphatidylinositol 3-Kinase/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Random Allocation
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*metabolism
EDAT- 2020/10/26 06:00
MHDA- 2021/07/22 06:00
CRDT- 2020/10/25 20:18
PHST- 2020/10/25 20:18 [entrez]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/07/22 06:00 [medline]
PST - ppublish
SO  - J BUON. 2020 Jul-Aug;25(4):2066-2070.